Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22-Reference-Cited by-同舟云学术

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Published:2024-03 Issue:1 Volume:32 Page:200775
ISSN:2950-3299
Container-title:Molecular Therapy: Oncology
language:en
Short-container-title:Molecular Therapy: Oncology

Author:

McComb Scott^ORCID,Arbabi-Ghahroudi Mehdi,Hay Kevin A.,Keller Brian A.,Faulkes Sharlene,Rutherford Michael,Nguyen Tina,Shepherd Alex,Wu Cunle,Marcil Anne,Aubry Annie,Hussack Greg,Pinto Devanand M.,Ryan Shannon,Raphael Shalini,van Faassen Henk,Zafer Ahmed,Zhu Qin,Maclean Susanne,Chattopadhyay Anindita,Gurnani Komal,Gilbert Rénald,Gadoury Christine,Iqbal Umar,Fatehi Dorothy,Jezierski Anna,Huang Jez,Pon Robert A.,Sigrist Mhairi,Holt Robert A.,Nelson Brad H.,Atkins Harold,Kekre Natasha,Yung Eric,Webb John,Nielsen Julie S.,Weeratna Risini D.

Funder

National Research Council Canada

Publisher

Elsevier BV

Reference44 articles.

1. CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions;Gill,2021

2. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies;Xu;Front. Immunol.,2019

3. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel;Plaks;Blood,2021

4. Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies;Atilla;Transl. Oncol.,2022

5. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia;Pan;Leukemia,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Flow Cytometry–Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells;BIO-PROTOCOL;2024